

DRUG UTILIZATION REVIEW BOARD
July 21, 2021
MO HealthNet (MHD)
VIA WEBEX ONLY

Committee Members Present:

Susan Abdel-Rahman, PharmD, Chair
Charlene Heyde, RPH
Sandra Bollinger, PharmD
Julie Ferguson, DO
Lisa Pierce, MD
Jennifer Passanise, FNP
Stacy Mangum, PharmD
Ginger Nicol, MD, CEDS
Rick Kegler, PharmD, MBA
Kim Eisenstein, MD

MO HealthNet Staff Present:

Joshua Moore, PharmD, Director of
Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Angela Wilson, Pharmacy Operations
Manager
Elizabeth Sissom, RN, Clinical
Management
Timothy Kling, MD, Acting Medical
Director
Elizabeth Short, Program Development
Specialist
Connie Sutter, Fiscal Manager
Jaime Jones, Drug Rebate Medicaid
Specialist
Olivia Rush, PharmD, Program Integrity
Pharmacist

Carmen Burton, Administrative Assistant
Malcolm Holtz, PharmD Student '22

Contractors in Attendance:

Chelsea Pendleton, RN, BSN, Wipro
Valerie Schmitz, RN, BSN, Wipro
April Ash, PharmD, Conduent
Blake Shrout, PharmD, AAHIVP,
Conduent
Jennifer Colozza, PharmD, Conduent
Karen Powell, PharmD, Conduent
Katie Wilbers, PharmD, Conduent
Luke Boehmer, PharmD, Conduent
Mary-Beth Plum, PharmD, Conduent
Megan Fast, PharmD, Conduent
Serena Barden, PharmD, BCPS,
Conduent
Paul Fung, PharmD, Conduent
Farrah Tucker, PharmD Student '22
Sandra Kapur, PharmD, Conduent

Others Attending:

Aaron Shaw
Audrey Rattan
Ballmck
Bobbi Bentz
Brian Strickland
Brooke Wilkins

CDL
Donna Birchette
Emma Selm-Keck
Evan Rushing
Gina Heinen
Holly Budlong
James Baumann
Jen Shumsky
Jessica Petrie
John
Jordan Feuerborn
Karen Malamut
Kathrin Kucharski
Kevin Hinthron
Kurt Hendrickson
Matthew Bradley
Megan Bell
Melissa Basil
Michael Holmes
Michele Shirley
Nicole Linn
Phillip King
Ray Kong
Ricki Roberson
Rob Kilo
Robert Firnberg
Roberto Pedraza
Tom Guyer

<p align="center">Welcome, Introductions and Opening Remarks</p>	<p>Susan Abdel-Rahman, Board Chair, called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, introduced himself along with new DUR board members Kim Eisenstein and Julie Ferguson, new Conduent Account Director Paul Fung, and pharmacy students Malcolm Holtz and Farrah Tucker. Joshua facilitated the meeting on behalf of the MO HealthNet Division.</p>
<p align="center">Minutes Review</p>	<p>Discussion: Minutes were reviewed from the April 2021 meeting.</p> <p>Decision: The Board voted to accept these approved minutes with no additional revisions.</p>
<p align="center">Pharmacy Program and Budget Update</p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - June 2021 Eligibles by Group - July 2020 – June 2021 Expenditures by Enrollment Group - July 2020 – June 2021 Expenditures by Service - FY21 Pharmacy Spend vs July 2020 – June 2021 Total Medicaid Spend - FY21 July 2020 – June 2021 Pharmacy Expenditures - Top 4 Drug Classes per Fiscal Year - July 2020 – June 2021 Rare Disease Expenditures - FY19 – FY21 Rare Disease Expenditures - Project Hep Cure Updates <ul style="list-style-type: none"> o Hepatitis C elimination plan in the MHD population (~6,000 participants) o Upcoming training opportunities for providers o July 1st implementation o Hepatitis C ShowMe ECHO Program o DSS website with progress highlights: https://dss.mo.gov/mhd/hepc/ - Reminder: pharmacy copayments are waived now through the end of the public health emergency which has been extended - Usual and Customary Definitions

	<ul style="list-style-type: none"> - Reimbursement <ul style="list-style-type: none"> o 340B Reimbursement Modification <ul style="list-style-type: none"> ▪ MHD bulletin: https://dss.mo.gov/mhd/providers/pdf/bulletin43-44.pdf ▪ SPA approved June 2021 and final rule expected to be in place Jan 1, 2022 o Pharmacy Program Reimbursement changes <ul style="list-style-type: none"> ▪ MHD bulletin: https://dss.mo.gov/mhd/providers/pdf/bulletin43-46.pdf - Prescription Drug Monitoring Program <ul style="list-style-type: none"> o New SUPPORT Act requirements effective October 1; MHD bulletin: https://dss.mo.gov/mhd/providers/pdf/bulletin43-31.pdf o State wide PDMP implementation expected in 2023 o St. Louis County PDMP access - RSV Updates (see MHD Hot Tip) - High Risk Combinations Edit Updates <ul style="list-style-type: none"> o Increased utilization of Narcan = showing success in initiative; o Program integrity auditing is in place to prevent pharmacies from circumventing edit
Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/dur/meeting.htm</p>

New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action. - Questions arose on the classification of Etesevimab as open access; it was explained the classification was due to the enhanced match during the public health emergency even if agents fall out of favor or distribution is paused. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
Clinical & Fiscal Edits With No Annual Changes	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Ampyra Clinical Edit o Elagolix Clinical Edit o Gamifant Clinical Edit o Koselugo Clinical Edit o Luxturna Clinical Edit o Oxervate Clinical Edit o Reblozyl Clinical Edit o Synagis Clinical Edit o Tepezza Clinical Edit o Tolvaptan Clinical Edit o Zometa Clinical Edit - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center">CAR-T Cell Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Crysvita Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Duchenne Muscular Dystrophy Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Entresto Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Extended Supply Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">HBV Nucleotide Analog Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center">Imcivree Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Iron, Injectable Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Nulibry Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Oxazolidinone Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Palynziq Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center">PTH Agents Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Verquvo Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Zokinvy Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center">Preferred Drug List Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Amylin Analogs o Antibiotics, Vaginal o Bile Salt Agents o Cephalosporin Agents o Electrolyte Depleting Agents, Phosphate Lowering o Electrolyte Depleting Agents, Potassium Lowering o Fluoroquinolone Agents, Oral o Insulin, Mixed o Insulin, Non-Analogs o Penicillin Agents o Sulfonylureas, Second Generation o Targeted Immune Modulators, IL6 Receptor Inhibitors o Thrombocytopenia Agents - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Alpha-Glucosidase Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Antibiotics, GI Oral PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose on the trial and failure of vancomycin prior to use of fidaxomicin even though the IDSA guidelines list fidaxomicin as a first line agent; it was explained that the pricing of both agents was the ultimate driver of decision. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center">Antibiotics, Mupirocin Topical PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Antihyperuricemic Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Benign Prostatic Hyperplasia (BPH) Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Biguanides & Combinations PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Bone Ossification Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center">Colony Stimulating Factors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Cryopyrin-Associated Periodic Syndrome Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">DPP-IV Inhibitors & Combinations PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Erythropoiesis Stimulating Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">GLP-1 Receptor Agonists & Combinations PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Clarification was provided that MHD does not have A1c requirements for this class of medication. - Questions arose on the approved age for liraglutide and if MHD allowed a pathway for coverage in this age range; it was explained that Victoza is approved down to 10 years of age and MHD has that criteria in place. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center">Growth Hormone Agents, Somatropin PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Growth Hormone & Growth Hormone Releasing Factors, Select Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Insulin, Long Acting PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Insulin, Rapid Acting PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">LHRH/GnRH Agents, Non-Oral PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p>Macrolides PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Meglitinides PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Methotrexate Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Multiple Sclerosis Agents, Injectable PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Multiple Sclerosis Agents, Oral PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center">SGLT2 Inhibitors & Combinations PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Targeted Immune Modulators, IL17 Antibody/IL17 Receptor Antagonists PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Targeted Immune Modulators, IL23 Inhibitors & IL23/IL12 Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Targeted Immune Modulators, JAK Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Targeted Immune Modulators, Select Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p>Targeted Immune Modulators, TNF Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Tetracycline Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Thiazolidinediones & Combinations PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Urinary Tract Antispasmodics PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Program Utilization Information – Conduent Update</p>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 3rd Quarter 2021 (January, February, March) - Top 25 Drugs by Paid Number 3rd Quarter 2021 (January, February, March) - Call Center Statistics May 2021 - CyberAccess User Statistics May 2021 - CyberAccess Logging Information - New Drug Statistics May 2021

<p style="text-align: center;">Other Business</p>	<p>DUR Board Updates:</p> <ul style="list-style-type: none"> - The October meeting will now allow up to 5 minutes for public comment - The October meeting will most likely be in person for some attendees; MHD to keep everyone informed - Relias, a company that works with MHD on the DUR mailing, will be speaking to the Board at a future meeting <p>MHD Initiatives:</p> <ul style="list-style-type: none"> - Review of cost and claim counts of medications that were approved through the accelerated approval process
<p style="text-align: center;">Closing</p>	<p>Sandra Bollinger motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. The next meeting of the Drug Utilization Review Board is scheduled via WebEx only on Wednesday, October 20, 2021 unless otherwise specified.</p>

Roll Call for July 21, 2021				
	<u>Action Item</u>			
<u>Board Member</u>	April Meeting Minutes	All Recommendations: Block Vote for CE, FE and PDL Edits	Closing	Adjournment
Susan Abdel-Rahman	Y	Y	Y	Y
Charlene Heyde	Y	Y	Y	Y
Sandra Bollinger	Y	Y	MY	Y
Julie Ferguson	Y	Y	Y	Y
Lisa Pierce	MY	SY	SY	SY
Jennifer Passanise	Y	Y	Y	Y
Stacy Mangum	SY	MY	Y	Y
Ginger Nicol	Y	Y	Y	MY
Rick Kegler	Y	Y; AB from Palynziq CE	Y	Y
Kim Eisenstein	Y	Y	Y	Y

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain